Sensei Biotherapeutics (SNSE) Price & Analysis

Compare

211 Followers

SNSE Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.00 - $17.40

Previous CloseN/A

Volume8.76M

Average Volume (3M)10.16K

Market Cap

$13.01M

Enterprise Value-$21.20M

Total Cash (Recent Filing)$34.33M

Total Debt (Recent Filing)$3.21M

Price to Earnings (P/E)―

Beta1.83

Next Earnings

Nov 11, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding1,260,403

10 Day Avg. Volume14,792

30 Day Avg. Volume10,160

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-1.63

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit157.02

Enterprise Value/Ebitda0.74

Forecast

1Y Price Target

$67.50

Price Target Upside554.07% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsEncouraging preliminary dose expansion data in 'hot' tumors has been reported, showing high disease control rates in patients with advanced solid tumors.

Drug TolerabilitySolnerstotug continues to be well tolerated with no dose-limiting toxicities reported in the trial.

Potential Drug ApprovalSNS-101 could potentially be the first anti-VISTA monoclonal antibody approved as a therapeutic agent.

Bears Say

Clinical Trial EfficacyNo complete or partial responses were observed in patients with 'cold' tumors, indicating limited efficacy in this group.

Earnings MissSensei reported 4Q24 EPS of ($0.31), compared to an estimate of ($0.29).

Financial PerformanceThe FY25 EPS estimate has been decreased to ($0.94) from ($0.76).

Sensei Biotherapeutics News

Sensei Biotherapeutics Regains Nasdaq Compliance

Sensei Biotherapeutics ( ($SNSE) ) has issued an update. On July 2, 2025, Sensei Biotherapeutics announced that it...

25d ago

SNSE

Sensei price target raised to $35 at Stephens to reflect 1-for-20 reverse split

Stephens raised the firm’s price target on Sensei Biotherapeutics (SNSE) to $35 from $4 and keeps an Overweight...

1M ago

SNSE

Sensei Biotherapeutics Inc trading halted, news pending

19:50 EDT Sensei Biotherapeutics (SNSE) Inc trading halted, news pending Published first on TheFly – the ultimate source...

2M ago

SNSE

Upcoming Stock Splits This Week (June 16 to June 20) – Stay Invested

These are the upcoming stock splits for the week of June 16 to June 20, based on TipRanks’ Stock...

2M ago

NCI

RGC

Sensei Biotherapeutics Announces Reverse Stock Split

Sensei Biotherapeutics ( ($SNSE) ) has shared an announcement. On June 12, 2025, Sensei Biotherapeutics announced a one-for-twenty...

2M ago

SNSE

Sensei announces 1-for-20 reverse stock split

Sensei Biotherapeutics (SNSE) announced that it will implement a 1-for-20 reverse stock split of its issued and outstanding...

2M ago

SNSE

Sensei Biotherapeutics assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Sensei Biotherapeutics (SNSE) with a Buy rating and $5 price target Sensei is...

2M ago

SNSE

Sensei Biotherapeutics Approves Reverse Stock Split

The latest update is out from Sensei Biotherapeutics ( ($SNSE) ). On May 21, 2025, Sensei Biotherapeutics held...

2M ago

SNSE

Sensei Biotherapeutics Reports Promising Q1 2025 Results

Sensei Biotherapeutics, Inc. ( ($SNSE) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

SNSE

Sensei Biotherapeutics reports Q1 EPS (27c) vs (32c) last year

“This was a breakthrough quarter for Sensei,” said John Celebi, President and CEO. “We observed favorable signs of...

3M ago

SNSE

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

4M ago

CDT

NVO

Sensei Biotherapeutics Reports Promising 2024 Results

Sensei Biotherapeutics, Inc. ( ($SNSE) ) has released its Q4 earnings. Here is a breakdown of the information...

4M ago

SNSE

Sensei Biotherapeutics price target raised to $4 from $3.50 at Oppenheimer

Oppenheimer raised the firm’s price target on Sensei Biotherapeutics (SNSE) to $4 from $3.50 and keeps an Outperform...

4M ago

SNSE

Sensei Biotherapeutics reports FY24 EPS ($1.20) vs ($1.22) last year

“2024 was a pivotal year for Sensei, as we advanced solnerstotug through dose expansion and began to demonstrate...

4M ago

SNSE

SNSE FAQ

What was Sensei Biotherapeutics’s price range in the past 12 months?

Sensei Biotherapeutics lowest stock price was $5.00 and its highest was $17.40 in the past 12 months.

What is Sensei Biotherapeutics’s market cap?

Sensei Biotherapeutics’s market cap is $13.01M.

When is Sensei Biotherapeutics’s upcoming earnings report date?

Sensei Biotherapeutics’s upcoming earnings report date is Nov 11, 2025 which is in 100 days.

How were Sensei Biotherapeutics’s earnings last quarter?

Currently, no data Available

Is Sensei Biotherapeutics overvalued?

According to Wall Street analysts Sensei Biotherapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sensei Biotherapeutics pay dividends?

Sensei Biotherapeutics does not currently pay dividends.

What is Sensei Biotherapeutics’s EPS estimate?

Sensei Biotherapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sensei Biotherapeutics have?

Sensei Biotherapeutics has 1,260,403 shares outstanding.

What happened to Sensei Biotherapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Sensei Biotherapeutics?

Currently, no hedge funds are holding shares in SNSE

Sensei Biotherapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-64.18%

Trailing 12-Months

Asset Growth

-42.61%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sensei Biotherapeutics

Sensei Biotherapeutics, Inc. (SNSE) is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immunotherapies for the treatment of cancer. The company operates in the biotechnology and pharmaceutical sectors, leveraging its innovative ImmunoPhage™ platform to develop a pipeline of novel therapies aimed at modulating the immune system to recognize and destroy cancer cells. Sensei's core product candidates are designed to target various types of cancer, offering potential new treatment options for patients with unmet medical needs.

Sensei Biotherapeutics (SNSE) Earnings & Revenues

SNSE Earnings Data >

SNSE Stock 12 Month Forecast

Average Price Target

$67.50

▲(554.07%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","29":"$29","53":"$53","77":"$77","101":"$101"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$67.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,29,53,77,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2024","6":"May<br/>2024","9":"Nov<br/>2024","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.3,13.507692307692308,20.715384615384615,27.923076923076923,35.13076923076923,42.33846153846154,49.54615384615384,56.753846153846155,63.96153846153846,71.16923076923077,78.37692307692308,85.58461538461539,92.79230769230769,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.3,11.007692307692308,15.715384615384615,20.423076923076923,25.130769230769232,29.83846153846154,34.54615384615384,39.253846153846155,43.96153846153846,48.669230769230765,53.37692307692308,58.08461538461538,62.79230769230769,{"y":67.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.3,8.507692307692308,10.715384615384615,12.923076923076923,15.130769230769232,17.33846153846154,19.546153846153846,21.753846153846155,23.961538461538463,26.169230769230772,28.37692307692308,30.584615384615386,32.792307692307695,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.4,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.8,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.73,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.46,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.2,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.79,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.1,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.8,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.32,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >